Growth funds roar back as semiconductor stocks rocket

Munro Partners’ $1.7 billion Global Growth Fund was among the biggest beneficiaries of last month’s rally, returning 10 per cent in April thanks to its positions in Taiwan Semiconductor Manufacturing Company, Broadcom and Amazon.

Alex Gluyas

Growth funds roar back as semiconductor stocks rocket

May 18, 2026
Munro Partners’ $1.7 billion Global Growth Fund was among the biggest beneficiaries of last month’s rally, returning 10 per cent in April thanks to its positions in Taiwan Semiconductor Manufacturing Company, Broadcom and Amazon.
Read Transcript

Australia’s top technology investors have bounced back from a tough start to the year as booming demand for chips that power artificial intelligence unleashes an explosive rally in semiconductor stocks, fuelling bumper returns in April for growth-focused funds.

Investors have piled into technology stocks amid signs that the giant AI providers are continuing to ramp up spending. The four biggest spenders – Amazon, Microsoft, Alphabet and Meta – are expected to plough nearly $US700 billion ($982 billion) into capital expenses this year.

That has triggered a surge in earnings expectations for semiconductor stocks, which are, in the first quarter, on track to jump 84 per cent from a year ago. The Philadelphia semiconductor index has rallied about 60 per cent this year as investors tussle for a slice of the booming profits.

Munro Partners’ $1.7 billion Global Growth Fund was among the biggest beneficiaries of last month’s rally, returning 10 per cent in April thanks to its positions in Taiwan Semiconductor Manufacturing Company (TSMC), Broadcom and Amazon.

“What you’re seeing right now is the equity market realising what’s been happening for two years now, which is that hyperscale capex just keeps going up because they keep planning new projects,” said Munro chief investment officer Nick Griffin.

“For some unknown reason, the equity market has consistently tried to take the opposite view, but now you’re seeing everyone cross the aisle very quickly because it has become dramatically apparent that the AI capex build-out is only just getting started.”

Software stocks were battered earlier this year amid fears that their business models would be disrupted by more powerful AI tools. While that hurt the returns of many growth funds, the recent rally in semiconductor stocks has triggered a resurgence.

Griffin believes the shift in market sentiment has been fuelled by the surge in AI provider Anthropic’s average revenue run rate from $US9 billion at the end of last year to $US30 billion ($42 billion). The annual run rate – a popular benchmark among tech start-ups – extrapolates the current sales level over a full year.

Anthropic’s windfall has been driven by growing demand for tokens, which are the fundamental units of text that AI models use to understand and process language.

“People around the world are finding great uses for agentic AI,” Griffin said. “Rather than asking AI a question, and it gives you an answer, people are sending computers off to do tasks that take days, and those tasks are using between 150,000 and over 1 million times more compute than just asking ChatGPT a question.

“So Anthropic is giving us a real-time update of the explosion of token growth, which is reflected in its revenue going parabolic.”

Loftus Peak chief investment officer Alex Pollak said Wall Street’s quarterly reporting season revealed that the rollout of AI infrastructure is on track and heading towards an even larger magnitude than previously expected.

Loftus’ $751 million Global Disruption Fund returned 10.6 per cent as holdings in Alphabet, Amazon, and Nvidia rallied alongside semiconductor stocks Advanced Micro Devices, TSMC and Broadcom.

“Despite the sudden upward movements in many of these chip stocks, the sheer demand for AI chips is still increasing,” Pollak said.

One of the best-performing funds last month was the Frazis Fund, helmed by tech investor Michael Frazis, which returned a whopping 25 per cent and is now up more than 70 per cent over the past 12 months.

While Frazis started April with one of its highest cash balances, he bought aggressively throughout the month amid signs there would be an imminent wave of buying from quantitative investors.

“We knew the buying was coming, but we didn’t expect it so soon,” he said.

While the firm’s exposure to the semiconductor sector was weighted heavily towards mega-cap stocks such as Nvidia and Broadcom, it also had small positions in so-called bottleneck companies, which provide the infrastructure, power, or components needed to build and operate AI.

Australia’s top technology investors have bounced back from a tough start to the year as booming demand for chips that power artificial intelligence unleashes an explosive rally in semiconductor stocks, fuelling bumper returns in April for growth-focused funds.

Investors have piled into technology stocks amid signs that the giant AI providers are continuing to ramp up spending. The four biggest spenders – Amazon, Microsoft, Alphabet and Meta – are expected to plough nearly $US700 billion ($982 billion) into capital expenses this year.

That has triggered a surge in earnings expectations for semiconductor stocks, which are, in the first quarter, on track to jump 84 per cent from a year ago. The Philadelphia semiconductor index has rallied about 60 per cent this year as investors tussle for a slice of the booming profits.

Munro Partners’ $1.7 billion Global Growth Fund was among the biggest beneficiaries of last month’s rally, returning 10 per cent in April thanks to its positions in Taiwan Semiconductor Manufacturing Company (TSMC), Broadcom and Amazon.

“What you’re seeing right now is the equity market realising what’s been happening for two years now, which is that hyperscale capex just keeps going up because they keep planning new projects,” said Munro chief investment officer Nick Griffin.

“For some unknown reason, the equity market has consistently tried to take the opposite view, but now you’re seeing everyone cross the aisle very quickly because it has become dramatically apparent that the AI capex build-out is only just getting started.”

Software stocks were battered earlier this year amid fears that their business models would be disrupted by more powerful AI tools. While that hurt the returns of many growth funds, the recent rally in semiconductor stocks has triggered a resurgence.

Griffin believes the shift in market sentiment has been fuelled by the surge in AI provider Anthropic’s average revenue run rate from $US9 billion at the end of last year to $US30 billion ($42 billion). The annual run rate – a popular benchmark among tech start-ups – extrapolates the current sales level over a full year.

Anthropic’s windfall has been driven by growing demand for tokens, which are the fundamental units of text that AI models use to understand and process language.

“People around the world are finding great uses for agentic AI,” Griffin said. “Rather than asking AI a question, and it gives you an answer, people are sending computers off to do tasks that take days, and those tasks are using between 150,000 and over 1 million times more compute than just asking ChatGPT a question.

“So Anthropic is giving us a real-time update of the explosion of token growth, which is reflected in its revenue going parabolic.”

Loftus Peak chief investment officer Alex Pollak said Wall Street’s quarterly reporting season revealed that the rollout of AI infrastructure is on track and heading towards an even larger magnitude than previously expected.

Loftus’ $751 million Global Disruption Fund returned 10.6 per cent as holdings in Alphabet, Amazon, and Nvidia rallied alongside semiconductor stocks Advanced Micro Devices, TSMC and Broadcom.

“Despite the sudden upward movements in many of these chip stocks, the sheer demand for AI chips is still increasing,” Pollak said.

One of the best-performing funds last month was the Frazis Fund, helmed by tech investor Michael Frazis, which returned a whopping 25 per cent and is now up more than 70 per cent over the past 12 months.

While Frazis started April with one of its highest cash balances, he bought aggressively throughout the month amid signs there would be an imminent wave of buying from quantitative investors.

“We knew the buying was coming, but we didn’t expect it so soon,” he said.

While the firm’s exposure to the semiconductor sector was weighted heavily towards mega-cap stocks such as Nvidia and Broadcom, it also had small positions in so-called bottleneck companies, which provide the infrastructure, power, or components needed to build and operate AI.

Disclaimer: This material has been prepared by Australian Financial Review, published on May 18, 2026. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.